TGFB1 and idiopathic pulmonary fibrosis: We speculate that AM and RPR suppressed TGF-β1/PI3K/Akt, MAPK, and VEGF signaling pathways by targeting these pharmacological targets, subsequently ameliorating ECM deposition and inflammation in IPF.